Navigation Links
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
Date:3/13/2009

ter Capital Management, LLC and associated companies decreased holdings in the Company to 2,814,932 common shares, representing 4.8 per cent voting rights attached to the issued common share capital of the Company, being 58,216,309 common shares. This information is being provided in order to comply with the rules for AIM listed companies.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in over 12 countries, In more than 3,500 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from o
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
2. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
3. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
4. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
5. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
6. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
7. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
8. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
9. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
10. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
11. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 31, 2015   Halyard Health (NYSE: ... was awarded a new purchasing agreement with HealthTrust ... March 1, 2015, Halyard,s standard and ASTM-rated face ... will be available to HealthTrust members made up of ... surgery centers, physician practices and alternate care facilities. ...
(Date:3/31/2015)... , March 31, 2015 Immune Pharmaceuticals ... today that it intends to expand its planned bullous ... monoclonal antibody targeting eotaxin-1. Bullous Pemphigoid is an orphan ... patients in the US and Europe ... start enrolling patients in a Phase II clinical trial ...
(Date:3/31/2015)... 31, 2015  Oxis International, Inc. (OXIS) (OXI.PA) a ... commercialization, announced today Oxis CEO Tony Cataldo ... common shares on the Euronext exchange. Oxis shares will ... OXIS.   Oxis Chairman and CEO ... forward with its strategies launched in 2014 and 2015, ...
Breaking Medicine Technology:Halyard Health Signs First GPO Contracts As Independent Company 2Halyard Health Signs First GPO Contracts As Independent Company 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 2Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 4Oxis International Inc. Announces Request for Euronext Trading Suspension 2
... Jan. 24, 2012  Cohera Medical, Inc.®, a leading innovator ... announced today that it has received Investigational Device ... and Drug Administration ("FDA") to begin a prospective, ... TissuGlu® Surgical Adhesive in the United ...
...  MedAssurant, Inc., a leading provider of data-driven ... also known as BlueCross BlueShield of Puerto ... have selected MedAssurant,s Star Advantage™, Prospective Advantage® ... providing an integrated solution for identifying and ...
Cached Medicine Technology:Cohera Medical Receives IDE Approval to Begin Pivotal Clinical Trial for TissuGlu® Surgical Adhesive in the U.S. 2Triple-S Salud and American Health Medicare Partner With MedAssurant 2Triple-S Salud and American Health Medicare Partner With MedAssurant 3Triple-S Salud and American Health Medicare Partner With MedAssurant 4Triple-S Salud and American Health Medicare Partner With MedAssurant 5
(Date:4/1/2015)... TCS Healthcare Technologies (TCS), a leading provider of ... population health arenas, is pleased to announce a webinar ... fully integrated with the ACUITY platform. , The webinar, ... will be led by Jeff Frater, RN, BSN, Director ... feature-rich portal as well as the importance of an ...
(Date:4/1/2015)... IL (PRWEB) April 01, 2015 Poisonous ... greatly from climate change in recent years, increasing significantly ... an allergic reaction if exposed to poison plants (according ... enthusiasts and families prepare for summer adventures in nature, ... uncomfortable poison plant reaction is greater than ever. This ...
(Date:3/31/2015)... National (PRWEB) April 01, 2015 Every ... the S.A.D. (standard American diet) contains things banned in ... illness sky rockets every year. AlignLife Chiropractic & Natural ... patients but also their communities they can reduce the ... Throughout the year each AlignLife clinic offers workshops at ...
(Date:3/31/2015)... Cosmetic Town, one of the most innovative ... adding news to its site while it redesigns to ... surgery and cosmetic medicine better use and navigate through ... the Cosmetic Town community is tingling at its bright ... site navigation, News and Blog section, will feature fresh ...
(Date:3/31/2015)... In honor of National Disability ... for buying from a NMEDA QAP certified dealer. ... a nonprofit organization that provides consumer guidance and ... installation of mobility equipment. The organization’s Quality Assurance ... consistently adhere to the highest quality safety and ...
Breaking Medicine News(10 mins):Health News:TCS Healthcare Technologies Releases Acuity Connect 2Health News:TCS Healthcare Technologies Releases Acuity Connect 3Health News:New Ivarest Poison Ivy Itch Spray Provides All-Day Comfort 2Health News:Cosmetic Town is Now Transforming so Consumer can Better Navigate 2Health News:Advanced Driving Systems Celebrates National Disability Month 2
... 15, 2012) As the supply of life-saving ... healthcare systems and policymakers to step up efforts ... available antibiotics through antimicrobial stewardship initiatives. ... Healthcare Epidemiology of America (SHEA), Infectious Diseases Society ...
... March 13, 2012Imagine that you have asthma, and rather than give ... have an attack, your doctor invites you to help write them? ... managing their health care, and would that ultimately make them happier ... Samir Gupta, a respirologist at St. Michael,s Hospital. His research ...
... carry rucksacks for school which top 10 to 15 per cent ... disorders, finds research published online in the Archives of Disease ... sedentary lifestyle, say the researchers. They assessed the back health ... from 11 schools in one province in North Western Spain. ...
... in the U.S., some 480,000 of them in California. Nearly ... with the disease. The overall burden of dementia is still ... of dementia cases. Yet as devastating as ... tremendous impact on family members, friends and caregivers. And while ...
... (ACS), the American Society for Colposcopy and Cervical Pathology ... have released new guidelines for the prevention and early ... reduction in the number of tests women get over ... benefits of testing while minimizing the harms, and include ...
... HealthDay Reporter , WEDNESDAY, March 14 (HealthDay News) -- Bans on ... to get people to quit smoking prevented close to 800,000 deaths ... a new study shows. The findings, published online March 14 ... represent just the tip of the iceberg as lung cancer is ...
Cached Medicine News:Health News:Leading infectious diseases experts call for increased focus on protecting antibiotics 2Health News:St. Michael's doctor uses wiki to empower patients and help them to develop asthma action plans 2Health News:Heavy rucksacks storing up back problems for many school-kids 2Health News:UCLA to launch unique, comprehensive Alzheimer's and dementia care program 2Health News:UCLA to launch unique, comprehensive Alzheimer's and dementia care program 3Health News:Health groups issue cervical cancer screening guidelines 2Health News:Health groups issue cervical cancer screening guidelines 3Health News:Anti-Smoking Efforts Saved 795,000 Lives Over 25 Years: Study 2Health News:Anti-Smoking Efforts Saved 795,000 Lives Over 25 Years: Study 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: